Following the U.S. FDA's IND approval for systemic lupus erythematosus indications on August 21, IMMUNEONCO-B (01541) has achieved another significant milestone with its internally developed CD47 and CD20-targeting bispecific molecule, amulirafusp alfa (IMM0306). On September 23, the company announced the latest results from its Phase Ib/IIa clinical study (NCT05771883) evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.

The newly released data demonstrate that in marginal zone lymphoma (MZL)—a condition with substantial unmet medical need—IMM0306 achieved an ORR of 92.3% and a CRR of 53.8%. Meanwhile, in follicular lymphoma (FL), the therapy delivered an ORR of 88.6% and a CR rate of 70.5%. Moreover, the combination regimen exhibited a remarkably low discontinuation rate across the entire MZL/FL patient population, with no CRS-related toxicity and no treatment-related deaths, establishing a therapeutic window defined by high efficacy and low toxicity.

How to approach the market opportunity

As two of the most common indolent lymphomas, FL and MZL are characterized by recurrent relapses requiring repeated treatment cycles, with limited therapeutic options available following first-line therapy failure. In terms of incidence, global statistics indicate approximately 122,000 new FL cases are diagnosed annually, predominantly affecting middle-aged and elderly populations. MZL, meanwhile, represents the second most common indolent lymphoma after FL, accounting for approximately 7%–15% of all non-Hodgkin lymphoma (NHL) cases. Given the prolonged average survival of patients with these two indications and their lifelong exposure to relapse-treatment cycles, a substantial unmet need persists for innovative therapies that combine potent efficacy with favorable safety profiles.

Within this market context, IMMUNEONCO-B's IMM0306 emerges as a novel therapeutic option offering superior efficacy and a safety profile better suited for long-term administration, providing patients worldwide with a more advantageous treatment alternative.

Why the comparative efficacy data matters

It is worth emphasizing that for these two indolent lymphoma types, treatment goals extend beyond significant objective responses to pursue deeper complete remission (CR), thereby reducing subsequent relapse risk and improving long-term survival. According to the latest study data disclosed by IMMUNEONCO-B, when benchmarked against existing immunotherapeutic regimens for R/R FL, the combination of IMM0306 plus lenalidomide demonstrates unprecedented response rates, durable and deep remissions, and an excellent safety profile in both R/R MZL and R/R FL patients.

For the R/R FL indication specifically, the IMM0306 plus lenalidomide regimen achieved ORR and CR rates of 88.6% and 70.5%, respectively. The CR rate significantly surpasses the historical 38.0% observed with the obinutuzumab plus lenalidomide regimen, indicating stronger tumor clearance capacity. Compared with the chemotherapy-free R2 regimen (rituximab plus lenalidomide), this approach achieves a two-fold improvement in CR (70.5% versus 34.7%). Furthermore, even when compared with the triple-drug combination of tafasitamab plus R2, the regimen maintains superior ORR and CR advantages.

For the MZL indication, the IMM0306 plus lenalidomide combination achieved ORR and CR rates of 92.3% and 52.8%, respectively. When compared with approved BTK inhibitors, which show an ORR of 57.8% and a CRR of 12%, the IMM0306-based regimen offers the potential for a more effective treatment option for MZL patients.

Mechanistically, IMM0306 functions as a CD47×CD20 myeloid cell engager (MCE), mediating ADCP/ADCC to eliminate B-cell lymphoma through macrophage/NK cell activity. This approach fundamentally circumvents the CRS and ICANS risks commonly associated with T-cell engagers such as CD20×CD3 bispecific antibodies. The safety data announced in this study provide robust validation of this mechanistic advantage: while maintaining low toxicity and high efficacy, no severe cytokine-release-syndrome-related toxicities or neurotoxicity were observed. This is particularly significant for indolent lymphoma patients requiring long-term disease management, potentially reducing clinical management complexity and improving treatment adherence and quality of life.

Looking ahead

The disclosure of these compelling data across two indications further confirms IMMUNEONCO-B's positioning in differentiated, independently developed innovation. The drug has already received FDA clinical trial approval in the United States, and beyond FL and MZL, clinical development is advancing efficiently across multiple indications including SLE, IgG4-RD, NMOSD, membranous nephropathy, and pSS. Should this potential first-in-class/best-in-class product secure regulatory approval and successful commercialization, it is poised to become a pivotal contributor to IMMUNEONCO-B's profitability, expanding the company's valuation potential and opening new avenues for growth.